NRG1: An Emerging Tumor Agnostic Target

Gain expert insight into the emerging role of NRG1 fusions as rare oncogenic drivers in a variety of solid tumors and learn about the targeted therapies in development from expert commentaries a text-based module and a downloadable slideset.

Share

Program Content

Activities

<em>NRG1</em> Fusion&ndash;Positive Tumors: Module
Neuregulin-1 (NRG1): An Emerging Tumor-Agnostic Target
Text Module
Congratulations: You achieved a completion on 04/09/2022

Released: February 02, 2022

Expires: February 01, 2023

Activities

Testing for NRG1-Driven Cancers
NRG1 Oncogenic Gene Fusions Across Solid Tumors: What You Should Know About Testing
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: November 16, 2021

Expires: November 15, 2022

Treatment of <em>NRG1</em>-Positive Cancers
NRG1 Oncogenic Gene Fusions Across Solid Tumors: Emerging New Agents for an Important Target
Clinical Thought
Congratulations: You achieved a completion on 04/09/2022

Released: February 28, 2022

Expires: February 27, 2023

Activities

NRG1 Fusion–Positive Tumors: Slides
NRG1: An Emerging Tumor-Agnostic Target
Slideset Download
Congratulations: You achieved a completion on 04/09/2022

Released: February 02, 2022

Expires: February 01, 2023

Faculty

cover img faculity

Maria E. Arcila, MD

Associate Attending, Pathology
Diagnostic Molecular Service
Pathology Department
Directory, Diagnostic Molecular Pathology Laboratory
Director, Molecular Hematopathology
Diagnostic Molecular Pathology and Hematopathology
Memorial Sloan Kettering Cancer Center
New York, New York

cover img faculity

Ryma Benayed, PhD

Associate Attending
Department of Pathology
Director, Clinical NGS Laboratory
Molecular Dx Service
Memorial Sloan Kettering Cancer Center
New York, New York

cover img faculity

Stephen Liu, MD

Assistant Professor of Medicine
Department of Medical Oncology
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC

cover img faculity

Joshua Sabari, MD

Assistant Professor of Medicine
Thoracic Medical Oncology
Phase I Experimental Therapeutics
Perlmutter Cancer Center
NYU Langone Health
New York, New York

Provided by

ProCE Banner

Supporters

Supported by an educational grant from

Elevation Oncology

Partners

American Society for Clinical Pathology

ProCE Banner